InvestSMART

Company announcements

leave blank for all companies
leave blank for all announcements
announcements
Reset Filters
~ We have limited the announcement data displayed on our website to the past 12 months to ensure its accuracy and usefulness.
Search Results
Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Granted first patent in Europe triggering payment from Lilly 18 Apr 2006 10:08AM $0.650 $0.011 fallen by 98.31%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Acrux patent portfolio advances in USA 1 Mar 2006 2:43PM $0.670 $0.011 fallen by 98.36%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Half Yearly Report & Half Year Accounts 16 Feb 2006 9:39AM $0.690 $0.011 fallen by 98.41%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Response to ASX Query re Share Price 10 Feb 2006 9:45AM $0.735 $0.011 fallen by 98.50%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Commitments Test Entity - Second Quarter Report 31 Jan 2006 4:20PM $0.630 $0.011 fallen by 98.25%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 New US patent & termination of licence to Napa Biosciences 8 Nov 2005 8:42AM $0.660 $0.011 fallen by 98.33%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Commitments Test Entity - First Quarter Report 27 Oct 2005 2:49PM $0.695 $0.011 fallen by 98.42%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Completion of enrolment in Evamist Phase 3 trial 12 Oct 2005 11:52AM $0.750 $0.011 fallen by 98.53%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Four new US patents granted to Acrux 26 Sep 2005 11:43AM $0.660 $0.011 fallen by 98.33%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Progress with Testosterone MD-Lotion for Men 7 Sep 2005 9:34AM $0.700 $0.011 fallen by 98.43%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Appendix 4E and 30 June 2005 Financial Report 25 Aug 2005 8:30AM n/a $0.011 n/a
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Commitments Test Entity - Fourth Quarter Report 29 Jul 2005 5:34PM $0.645 $0.011 fallen by 98.29%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Confirms Receipt of US$1million Licence Fee from Vivus 29 Jun 2005 12:31PM $0.550 $0.011 fallen by 98%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Positive data from Phase 1 trial of contraceptive spray 20 Jun 2005 8:33AM $0.570 $0.011 fallen by 98.07%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Targets Nausea in Cancer Patients-New Transdermal Treatment 1 Mar 2005 9:37AM $0.710 $0.011 fallen by 98.45%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Acrux partner VIVUS initiates Phase 3 study for Evamist 21 Dec 2004 12:23PM $0.890 $0.011 fallen by 98.76%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Transdermal treatment for severe pain to be dist by CSL 30 Nov 2004 8:46AM $0.900 $0.011 fallen by 98.78%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 New patent granted to Acrux resulting in milestone payment 19 Nov 2004 8:51AM $0.880 $0.011 fallen by 98.75%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Completion of Phase 1 clinical trial 6 Oct 2004 9:45AM $0.950 $0.011 fallen by 98.84%
Acrux Limited (ACR)
ORDINARY FULLY PAID
 Health Care $5 Admission to Official List 28 Sep 2004 3:34PM n/a $0.011 n/a

651 - 670 of 670 results

Page 27 of 27

  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.